The French biotech Qubit is joining forces with the American Nvidia to design drug candidates more quickly.
It still sounds like science fiction, but it’s a gamble that could transform medical research. The French biotech Qubit Pharmaceuticals is joining forces with the American Nvidia, leader in computing. Together, they want to create the world’s most powerful computing platform to accelerate drug discovery.
Founded in 2020, Qubit’s ambition is to design drug candidates in the fields of cancer, inflammatory diseases and antivirals with a view to selling them to laboratories that will carry out preclinical or clinical development. An uncommon economic model in the sector. To achieve this, the company has created a platform that can simulate the behavior of molecules and predict their effectiveness in the human body. In other words, rather than testing these molecules in vitro, it does so by calculation using supercomputers. What quickly test many molecules. But for that he needs…
This article is for subscribers only. You have 69% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login